Lexaria Bioscience
Open
$0.65
Prev. Close
$0.65
High
$0.65
Low
$0.65
Market Snapshot
$17.14M
-1.8
-0.50
$496.92K
7
Lexaria Bioscience Corp. is a biotechnology company, which engages in the provision of active pharmaceutical ingredients through its DehydraTECH drug delivery technology. The company is headquartered in Kelowna, British Columbia and currently employs 7 full-time employees. The company went IPO on 2009-10-28. The firm's patented drug delivery formulation and processing platform technology improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has also evidenced an ability to deliver some drugs effectively across the blood brain barrier. The Company’s segment includes Intellectual Property, B2B Production, and Research and Development. The company is advancing several research and development (R&D) activities in both preclinical and clinical programs. Its focus is the investigation and the incorporation of its DehydraTECH drug delivery technology with glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) to enhance absorption and reduce adverse side effects. The firm operates a licensed in-house research laboratory and holds an intellectual property portfolio with around 48 patents granted and many patents pending worldwide.
emptyResult
Lexaria Bioscience Corp. is a biotechnology company, which engages in the provision of active pharmaceutical ingredients through its DehydraTECH drug delivery technology. The company is headquartered in Kelowna, British Columbia and currently employs 7 full-time employees. The company went IPO on 2009-10-28. The firm's patented drug delivery formulation and processing platform technology improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has also evidenced an ability to deliver some drugs effectively across the blood brain barrier. The Company’s segment includes Intellectual Property, B2B Production, and Research and Development. The company is advancing several research and development (R&D) activities in both preclinical and clinical programs. Its focus is the investigation and the incorporation of its DehydraTECH drug delivery technology with glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) to enhance absorption and reduce adverse side effects. The firm operates a licensed in-house research laboratory and holds an intellectual property portfolio with around 48 patents granted and many patents pending worldwide.
Recently from Cashu
It seems the content you intended to provide for summarization is missing. Please share the text, and I’ll be glad to help with a title!
Sure, please provide the text you would like me to summarize, and I'll be happy to help!
Lexaria Bioscience: Revolutionizing Drug Delivery with Innovative DehydraTECH Technology
Lexaria Bioscience: Pioneering Innovations in Drug Delivery Systems Lexaria Bioscience stands at the forefront of the cannabis and pharmaceutical industries with its innovative drug delivery technolog…
Lexaria Bioscience: Revolutionizing Drug Delivery with DehydraTECH Technology
Lexaria Bioscience's Innovations in Drug Delivery: A Game Changer in the Industry Lexaria Bioscience is making significant strides in the pharmaceutical and nutraceutical sectors with its proprietary…
Lexaria Bioscience Advances Drug Delivery with Phase 1b Study of DehydraTECH Technology
Lexaria Bioscience Advances Drug Delivery Technology in Phase 1b Study Lexaria Bioscience Corp. has recently completed a significant milestone with the conclusion of its Phase 1b chronic study, GLP-1-…